Jaguar health completes final major regulatory filing for conditional new animal drug approval of canalevia (crofelemer) to treat exercise-induced diarrhea in dogs

Canalevia™ would be first and only fda-approved plant-based medicine for working dogs that suffer from diarrhea san francisco, ca / accesswire / february 10, 2022 / jaguar health, inc. (nasdaq:jagx), under its jaguar animal health tradename for the veterinary market, today announced that it has completed filing of the final major regulatory section with the u.s. food and drug administration's ("fda") center for veterinary medicine (cvm) to support conditional new animal drug approval of the company's oral plant-based drug candidate canalevia (crofelemer delayed-release tablets) to treat exercise-induced diarrhea (eid) in dogs. in december of 2021, jaguar animal health received conditional approval from the fda for canalevia™-ca1 for chemotherapy-induced diarrhea (cid) in dogs.
JAGX Ratings Summary
JAGX Quant Ranking